MedTrace Logo

Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

NCT07697547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2026-07-13

No results posted yet for this study

Summary

A multicenter retrospective study evaluating the effectiveness and safety of ustekinumab combined with low-dose upadacitinib in patients with refractory Crohn's disease.

Conditions

Interventions

DRUG

Upadacitinib

Upadacitinib was administered orally at a low dose of 15 mg/day or 30 mg/day for at least 12 weeks in combination with ustekinumab.

DRUG

Ustekinumab (UST)

Ustekinumab was administered as intravenous induction based on body weight, followed by subcutaneous maintenance therapy at 90 mg every 8 weeks, in combination with low-dose upadacitinib.

Sponsors & Collaborators

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Second Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Shanghai 10th People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07697547 on ClinicalTrials.gov